Antibody-Drug Conjugate
|
Mycenax collaborates to provide a comprehensive, one-stop Antibody-Drug Conjugate (ADC) CDMO services, covering the development and production of antibodies, linkers-payloads, and ADCs. These integrated services span from candidate ADC selection and process development to GMP manufacturing.
Leveraging the ConjuMX™ Toolbox, we offer a variety of conjugation methods and optimized processes to accelerate and shorten the timeline for new drug development. This platform is also well-suited for the development needs of novel conjugated drugs. |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
One-stop CDMO Services to Accelerate Drug Development |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Mycenax offers end-to-end solutions spanning from antibody cell line development, linker/drug chemical synthesis to conjugation processes. We provide flexible, stage-specific services tailored to client needs, integrating small-scale experiments through commercial production. This significantly reduces coordination costs while ensuring stable supply of antibodies and linker-payloads. Our optimized, validated processes enable seamless GMP-scale manufacturing readiness. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ConjuMX™: The Modular Conjugation Toolbox |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The ConjuMX™ Toolbox enables rapid screening of diverse linker-payload combinations and conjugation technologies during early development. It facilitates rapid generation of ADC samples for feasibility studies and analysis. Leveraging our ConjuMX™ Toolbox, we bring expertise from over 25 ADCs, achieving GMP-grade 50L scale production. Our innovative pipeline includes advancements in bispecific ADCs (BsADCs), trispecific ADCs (TsADCs), and dual-payload ADCs. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advanced Linker Technologies |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
MMA Linker: Mycenax’s Proprietary Multi-Arm Linker |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Mycenax has effectively applied its proprietary Multi-Arm Linker technology in ADC development, creating new opportunities and enhanced value for next-generation ADC. This advanced linker design significantly boosts drug-loading capacity, utilizing the synergistic or additive effects of dual payloads to address tumor heterogeneity and overcome drug resistance. As a result, Mycenax’s technology enables more effective and targeted cancer therapies. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
VLK Linker: RIN’s Proprietary VLK Linker Technology |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
The VLK linker is a novel, plasmin-cleavable technology designed for next-generation ADCs, uniquely optimized for non-internalizing targets within the tumor microenvironment. This proprietary technology has been integrated into Mycenax’s ADC platform through a strategic partnership. The collaboration has already yielded significant progress: Mycenax is currently manufacturing the investigational drug for RIN’s lead anti-TMEM180 antibody (Phase 1 study underway) and has successfully produced a high-quality, high-DAR (DAR8) ADC for RIN’s subsequent anti-IF-ADC pipeline using the VLK linker. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Strategic ADC Partners |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Mycenax Biotech has partnered with Japan's RIN Institute to integrate their proprietary Val-Leu-Lys (VLK) linker technology into Mycenax's ADC development platform. This global licensing deal combines RIN’s high-stability linker technology with Mycenax’s CDMO expertise to accelerate the production of next-generation, high-efficacy cancer therapies for the global market. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
KriSan offers small molecule drugs, linkers, payloads, and GMP production for ADC drugs for Mycenax’s global Antibody-Drug Conjugates CDMO business. Mycenax and KriSan announce a collaboration to strengthen their one-stop service chain for ADC. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Mycenax has established a strategic partnership with Spera Pharma and Krisan Biotech to deliver a comprehensive, end-to-end manufacturing solution for ADCs. By combining Spera’s mastery in process chemistry and aseptic GMP manufacturing with the collective expertise of Mycenax and Krisan, the alliance delivers a seamless "turnkey" solution covering the entire value chain—from Drug Substance (DS) to Drug Product (DP). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
Mycenax collaborates to provide a comprehensive, one-stop Antibody-Drug Conjugate (ADC) CDMO services, covering the development and production of antibodies, linkers-payloads, and ADCs. These integrated services span from candidate ADC selection and process development to GMP manufacturing.
Leveraging the ConjuMX™ Toolbox, we offer a variety of conjugation methods and optimized processes to accelerate and shorten the timeline for new drug development. This platform is also well-suited for the development needs of novel conjugated drugs. |
 |
 |
|
One-stop CDMO Services to Accelerate Drug Development |
|
Mycenax offers end-to-end solutions spanning from antibody cell line development, linker/drug chemical synthesis to conjugation processes. We provide flexible, stage-specific services tailored to client needs, integrating small-scale experiments through commercial production. This significantly reduces coordination costs while ensuring stable supply of antibodies and linker-payloads. Our optimized, validated processes enable seamless GMP-scale manufacturing readiness. |
 |
|
ConjuMX™: The Modular Conjugation Toolbox |
|
The ConjuMX™ Toolbox enables rapid screening of diverse linker-payload combinations and conjugation technologies during early development. It facilitates rapid generation of ADC samples for feasibility studies and analysis. Leveraging our ConjuMX™ Toolbox, we bring expertise from over 25 ADCs, achieving GMP-grade 50L scale production. Our innovative pipeline includes advancements in bispecific ADCs (BsADCs), trispecific ADCs (TsADCs), and dual-payload ADCs. |
 |
|
Advanced Linker Technologies |
|
MMA Linker: Mycenax’s Proprietary Multi-Arm Linker |
|
Mycenax has effectively applied its proprietary Multi-Arm Linker technology in ADC development, creating new opportunities and enhanced value for next-generation ADC. This advanced linker design significantly boosts drug-loading capacity, utilizing the synergistic or additive effects of dual payloads to address tumor heterogeneity and overcome drug resistance. As a result, Mycenax’s technology enables more effective and targeted cancer therapies. |
 |
|
VLK Linker: RIN’s Proprietary VLK Linker Technology |
|
The VLK linker is a novel, plasmin-cleavable technology designed for next-generation ADCs, uniquely optimized for non-internalizing targets within the tumor microenvironment. This proprietary technology has been integrated into Mycenax’s ADC platform through a strategic partnership. The collaboration has already yielded significant progress: Mycenax is currently manufacturing the investigational drug for RIN’s lead anti-TMEM180 antibody (Phase 1 study underway) and has successfully produced a high-quality, high-DAR (DAR8) ADC for RIN’s subsequent anti-IF-ADC pipeline using the VLK linker. |
 |
|
Strategic ADC Partners |
|
|
Mycenax Biotech has partnered with Japan's RIN Institute to integrate their proprietary Val-Leu-Lys (VLK) linker technology into Mycenax's ADC development platform. This global licensing deal combines RIN’s high-stability linker technology with Mycenax’s CDMO expertise to accelerate the production of next-generation, high-efficacy cancer therapies for the global market. |
|
|
KriSan offers small molecule drugs, linkers, payloads, and GMP production for ADC drugs for Mycenax’s global Antibody-Drug Conjugates CDMO business. Mycenax and KriSan announce a collaboration to strengthen their one-stop service chain for ADC. |
|
|
Mycenax has established a strategic partnership with Spera Pharma and Krisan Biotech to deliver a comprehensive, end-to-end manufacturing solution for ADCs. By combining Spera’s mastery in process chemistry and aseptic GMP manufacturing with the collective expertise of Mycenax and Krisan, the alliance delivers a seamless "turnkey" solution covering the entire value chain—from Drug Substance (DS) to Drug Product (DP). |